U.S., Jan. 8 -- ClinicalTrials.gov registry received information related to the study (NCT07324408) titled 'Multiple Ascending Dose Study of NH102 in Healthy Subjects' on Dec. 10, 2025.
Brief Summary: The purpose of this study is to assess the safety, tolerability and pharmacokinetics (PK) of NH102 when administered as multiple oral dose at escalating dose levels in healthy participants.
Study Start Date: March 10, 2022
Study Type: INTERVENTIONAL
Condition:
Depression
Intervention:
DRUG: NH102
tables orally
DRUG: Placebo
tables orally
Recruitment Status: COMPLETED
Sponsor: Jiangsu Nhwa Pharmaceutical Co., Ltd.
Disclaimer: Curated by HT Syndication....